Follow us on Twitter
twitter icon@FreshPatents


Pharmaceutically Acceptable Salts patents

      

This page is updated frequently with new Pharmaceutically Acceptable Salts-related patent applications.




 Intracellular delivery compounds patent thumbnailIntracellular delivery compounds
pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and their use in the intracellular delivery of antibodies.. .

 Gemcitabine prodrugs and uses thereof patent thumbnailGemcitabine prodrugs and uses thereof
And pharmaceutically acceptable salts thereof. For compounds of formula i, r1 and r2 are independently selected from the group consisting of h, —c(═o)—(ch2)2-aryl, and —c(═o)—(ch2)n—c(═o)—nh-aryl.

 Novel fused imidazobenzothiazole compounds patent thumbnailNovel fused imidazobenzothiazole compounds
The present invention relates to novel fused imidazobenzothiazole derivatives, their pharmaceutically acceptable salts, and their isomers, steroisomers, atropisomers, conformers, tautomers, polymorphs, hydrates, solvates and n-oxide. The present invention also encompasses pharmaceutically acceptable compositions of said compounds and process for preparing novel compounds.
Torrent Pharmaceuticals Limited


 Macrocyclic compounds as trk kinase inhibitors patent thumbnailMacrocyclic compounds as trk kinase inhibitors
Compounds of formula i: and pharmaceutically acceptable salts thereof, wherein ring a, ring b, w, m, d, r2, r2a r3 and r3a are as defined herein, are inhibitors of trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.. .
Array Biopharma, Inc.


 Azamorphinan derivatives and use thereof patent thumbnailAzamorphinan derivatives and use thereof
The application is directed to compounds of formula (i) and pharmaceutically acceptable salts and solvates thereof, wherein r1, r2, r3, r4, y, and z are defined as set forth in the specification. The invention is also directed to use of compounds of any one of formulae i-viii, and the pharmaceutically acceptable salts and solvates thereof, to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates.
Purdue Pharma L.p.


 8-(piperazin-1-yl)-1,2,3,4-tetrahydro-isoquinoline derivatives patent thumbnail8-(piperazin-1-yl)-1,2,3,4-tetrahydro-isoquinoline derivatives
The invention relates to compounds of formula (i) wherein r1, r2, r3, r4 and r5 are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds as medicaments, especially as modulators of the cxcr3 receptor.. .
Actelion Pharmaceuticals Ltd


 Substituted nitrogen-containing heterocyclic derivatives, pharmaceutical compositions comprising the same and applications ofantitumor thereof patent thumbnailSubstituted nitrogen-containing heterocyclic derivatives, pharmaceutical compositions comprising the same and applications ofantitumor thereof
Disclosed are new substituted nitrogen-containing heterocyclic derivatives represented by formula (i) as akt inhibitors, optical isomers, pharmaceutically acceptable salts or solvates thereof, wherein the definition of r1, r2, r3, r4, r5, r6, ring a, ring c, b, q, y, z and m is shown in the description for details. In addition, medicaments comprising the derivatives as active components are also disclosed, which can be useful for treating proliferative diseases, such as cancer and inflammation, especially diseases relating to akt kinase..
Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences


 Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases patent thumbnailCompounds, pharmaceutical composition and their use in treating neurodegenerative diseases
The present invention is directed to novel compounds of formula (i), pharmaceutically acceptable salts or solvates thereof, and their use.. .
Center Hospitalier Regional Et Universitare De Lille (chru)


 Cosmetic or pharmaceutical methods for the treatment and/or care of the skin and/or hair using tripeptides capable of stimulating cyclic adenosine monophosphate synthesis patent thumbnailCosmetic or pharmaceutical methods for the treatment and/or care of the skin and/or hair using tripeptides capable of stimulating cyclic adenosine monophosphate synthesis
Its stereoisomers, mixtures thereof and/or cosmetically or pharmaceutically acceptable salts thereof, in the treatment and/or care of conditions, disorders and/or diseases of the skin and/or hair by stimulating cyclic adenosine monophosphate synthesis (camp).. .

 Thienopyranones as kinase inhibitors patent thumbnailThienopyranones as kinase inhibitors
The invention relates to compounds of formula i (or pharmaceutically acceptable salts thereof) as defined herein, pharmaceutical compositions thereof, and their use in manufactures and methods for modulating biological processes including inhibition of kinase activity such as pi-3 kinase.. .
Signalrx Pharmaceuticals, Inc.


Thienopyranones as kinase and epigenetic inhibitors

The invention relates to methods of treating diseases including but not limited to, cancer, non-cancer proliferative disease, sepsis, autoimmune disease, viral infection, atheroscleosis, type 1 or 2 diabetes, obesity, inflammatory disease, or myc-depenent disorder including by modulating biological processes by the inhibition of pi3 kinase and/or bromodomain protein binding to substrates comprising the administration of a compound(s) of formula i-ix (or pharmaceutically acceptable salts thereof) as defined herein.. .
Signalrx Pharmaceuticals, Inc.

Heterocyclyl compounds as mek inhibitors

The present disclosure is related to heteroaryl compounds as mek inhibitors. These compounds include heteroaryl compounds of formula i, their pharmaceutically acceptable salts, combinations with suitable medicament and pharmaceutical compositions thereof.
Lupin Limited

Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and use

Wherein r1, r2, r3, and r4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by cftr, including cystic fibrosis, sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (i)..

N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and use

Wherein r1, r2, r3, r4, r5, and r6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by cftr, including cystic fibrosis, sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (i)..

Histone deacetylase inhibitors and compositions and methods of use thereof

Provided are certain histone deacetylase (hdac) inhibitors of formula i, or pharmaceutically acceptable salts thereof, compositions thereof, and methods of their use. The condition or disorder mediated by hdac comprises a neurodegenerative pathology.
Chdi Foundation, Inc.

Controlled release formulations of octreotide

A formulation of octreotide or pharmaceutically acceptable salts thereof, which provides controlled release of a therapeutically effective amount of octreotide for a period of at least about two months. Methods of treating acromegaly, decreasing growth hormone, decreasing igf-1, and treating conditions associated with carcinoid tumors and vipomas by administering a controlled release formulation of octreotide are provided herein..
Endo Pharmaceuticals Solutions Inc.

Crystalline forms of a bruton's tyrosine kinase inhibitor

Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Pharmacyclics Llc

Pharmaceutical compositions comprising danirixin for treating infectious diseases

Provided are compounds and pharmaceutically acceptable salts thereof, and combinations of compounds, their pharmaceutical compositions, their methods of preparation, and methods for their use in treating or preventing infectious disease.. .
Glaxosmithkline Intellectual Property (no. 2) Limited

Template-fixed peptidomimetics

The template-fixed β-hairpin peptidomimetics cyclo(-tyr-his-cys-ser-ala-dpro-dab-arg-tyr-cys-tyr-gln-lys-d-pro-pro), disulfide bond between cys4 and gys11, and pharmaceutically acceptable salts thereof, with x being ala or tyr, have cxcr4 antagonizing properties and can be used for where cancer is mediated or resulting from cxcr4 receptor activity. .
Polyphor Ltd.

Process for the preparation of macrolide antibacterial agents

Described herein are processes for the preparation of compounds of formula (i): and pharmaceutically acceptable salts, solvates, and hydrates thereof.. .
Cempra Pharmaceuticals, Inc.

Novel activators of glucokinase

The present invention provides for novel compounds of formulas i and ii and pharmaceutically acceptable salts and co-crystals thereof which have glucokinsae activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including type 1 and 2 diabetes, impaired glucose tolerance, insulin resistance and hyperglycemia.
Metabasis Therapeutics, Inc.

Helquats with heteroaromatic substituents, preparation thereof, and use thereof as g-quadruplex stabilizers

Helquat derivatives of general formula i, in which substituents r1 and r2 are independently selected from a group comprising h and c1 to c4 alkyl, up to three of s1,2, s1′,2′, s3,4 and s3′,4′ are present, each of s1,2, s1′,2′, s3,4 and s3′,4′ independently represents a linker consisting of a bivalent hydrocarbon chain having 3-6 carbon atoms, preferably hydrocarbon chain having 4 carbon atoms, and one to four atoms selected from the carbon atoms with the descriptor 2, 4, 2′, and 4′ are substituted with a substituent r3 of general formula ii, wherein r4 is substituted or unsubstituted heteroaryl, t1 and t2 are independent linkers that bridge atoms n5 with c8 and n5′ with c8′, wherein t1 and t2 independently represent a bivalent hydrocarbon chain having 2-5 carbon atoms, preferably 2 or 3 carbon atoms; and anions (x1)− and (x2)− independently represent anions of pharmaceutically acceptable salts.. .
Vysoka Skola Chemicko-technologicka V Praze

7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs thereof, and salts thereof and methods for their use in therapy

As defined in the specification, and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising the same. Methods of treatment, such as for cancer, are provided that comprise administering the compounds and their salts to a subject in need of such treatment..

Macrocycles with aromatic p2' groups as factor xia inhibitors

The present invention provides compounds of formula (i): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor xia inhibitors or dual inhibitors of fxia and plasma kallikrein.
Bristol-myers Squibb Company

Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives

The invention relates to fluorinated compounds and their use as integrin receptor antagonists. Novel fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives and pharmaceutically acceptable salts or solvates thereof and their use are described..
Scifluor Life Sciences, Inc.

Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors

And stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which a, b, d, e, x1, x2, x3 and x4 have the meanings given in the specification, which are inhibitors of ret kinase and are useful in the treatment and prevention of diseases which can be treated with a ret kinase inhibitor, including diseases or disorders mediated by a ret kinase.. .

Carboxamide derivatives and use thereof

And the pharmaceutically acceptable salts and solvates thereof, wherein z, het, r10, and e are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of formula i-a to treat a disorder responsive to the blockade of sodium channels.

Novel compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same

The present invention relates to novel compounds having histone deacetylase 6 (hdac6) inhibitory activity, isomers thereof, or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions comprising the same, a method of treating disease using the composition, and methods for preparing the novel compounds. The novel compounds according to the present invention have histone deacetylase 6 (hdac6) inhibitory activity, and are effective for the prevention or treatment of hdac6-associated diseases, including cancer, inflammatory diseases, autoimmune diseases, neurological diseases and neurodegenerative disorders..
Chong Kun Dang Pharmaceutical Corp.

Pyrazole compounds and their use as t-type calcium channel blockers

Wherein x, y, r1, r2, (r4)n, and (r5)m are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium t-channel blockers..

Fluorinated 2-amino-4-(benzylamino)phenylcarbamate derivatives

The invention relates to fluorinated compounds and their use as anti-epileptic, muscle-relaxing, fever-reducing and peripherally analgesically acting medications and as imaging agents. Novel fluorinated 2-amino-4-(benzylamino)phenyl carbamate derivatives of ezogabine and pharmaceutically acceptable salts or solvates thereof and their use are described..
Scifluor Life Sciences, Inc.

Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections

2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branchednucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of flaviviridae infections, including hcv infection, and other related conditions.
Universite De Montpellier

Compounds that inhibit mcl-1 protein

And pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer..

Antibacterial agents

As well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of such compounds.. .

Prmt5 inhibitors and uses thereof

Described herein are compounds of formula (i), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting prmt5 activity.
Epizyme, Inc.

Arginine methyltransferase inhibitors and uses thereof

Described herein are compounds of formula (i), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting arginine methyltransferase activity.
Epizyme, Inc.

Alpha-glucosidase inhibitors

R1 is thiophene, 2,4-di chloro phenyl, 2,6-di chloro phenyl, bromo phenyl, benzyl or nitrophenyl; and r2 is an aryl group, or stereoisomers or pharmaceutically acceptable salts thereof.. .

Treatment for lipodystrophy

The present invention provides a therapeutic compound of formula (i) and their pharmaceutically acceptable salts for the prevention and treatment of lipodystrophy caused because of hiv infection or combination therapy of hiv-1 protease inhibitors (pis) and/or reverse transcriptase inhibitors (nrtis) by neutralizing lipohypertrophy, lipoatrophy and metabolic abnormalities in hiv patient.. .
Cadila Healthcare Limited

Pharmaceutical composition for anti-vascular diseases and anti-tumor and use thereof

An anti-vascular diseases and antitumor pharmaceutical composition is provided in the present invention, and it includes effective ingredients including bleomycin antitumor antibiotic, adrenal glucocorticoid, epinephrine or pharmaceutically acceptable salts thereof in a weight ratio of (1-8):(2-5):(0.00005-0.001). The pharmaceutical composition provided can be used for treatment of vascular diseases and tumors..
Sun Yat-sen University

Anticholinergic neuroprotective composition and methods

The present invention relates to a pharmaceutical composition comprising propiverine, trospium or glycopyrrolate; and a non-anticholinergic antiemetic agent. It is also related to a pharmaceutical composition comprising a high dose of solifenacin or a pharmaceutically acceptable salts thereof; and a non-anticholinergic antiemetic agent.
Chase Pharmaceuticals Corporation

Substituted benzamides and methods of use thereof

And pharmaceutically acceptable salts thereof, wherein the variablesra, raa, subscipt n, ring a, x2, l, subscript m, x1, r1, r2, r3, r4, r5, and rn have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.. .

Pharmaceutically relevant aromatic-cationic peptides

The present technology provides peptides, methods of generating the peptides, and pharmaceutically acceptable salts of the peptides. In some embodiments, the peptide is 2′6′-dmt-d-arg-phe-lys-nh2 or phe-d-arg-phe-lys-nh2..
Stealth Biotherapeutics Corp

Therapeutically active 17-nitrogen substituted estratreinthiazole derivatives as inhibitors of 17.beta-hydroxysteroid dehydrogenase

The invention relates to compounds of formula (i) and pharmaceutically acceptable salts thereof wherein r2 to r7 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-hsd and in treatment or prevention of steroid hormone de-pendent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17β-hsd1 enzyme and/or requiring the lowering of the endogenous estradiol concentration.
Forendo Pharma Ltd

Therapeutically active estratrienthiazole derivatives as inhibitors of 17.beta-hydroxy-steroid dehydrogenase, type 1

The invention relates to compounds of formula (i) and pharmaceutically acceptable salts thereof wherein r2, r3, r4, r7 and r8 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-hsd1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17β-hsd1 enzyme and/or requiring the lowering of the endogenous estradiol concentration.
Forendo Pharma Ltd

Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof

The present invention relates to novel hydroxamic acids which are specific histone deacetylase (hdac) inhibitors and/or ttk/mps1 kinase inhibitors, including pharmaceutically acceptable salts thereof, which are useful for modulating hdac and/or ttk/mps1 kinase activity, pharmaceutical compositions comprising these compounds, and processes for their preparation.. .
The Regents Of The University Of Colorado, A Body Corporate

Benzoxazepin pi3k inhibitor compounds and methods of use

Benzoxazepin compounds of formula i, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: z1 is cr1 or n; z2 is cr2 or n; z3 is cr3 or n; z4 is cr4 or n; and b is a pyrazolyl, imidazolyl, or triazolyl ring fused to the benzoxepin ring, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of pi3k, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of formula i for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed..
Genentech, Inc.

Dihydropyrrolopyridine inhibitors of ror-gamma

pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ror. Also provided are pharmaceutical compositions comprising the novel compounds of formula (i) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders..

Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer

And pharmaceutically acceptable salts thereof, where r1, r2, r3, r4 and r5 have any of the meanings defined herein. The specification also relates to the use of compounds of formula (i) and salts thereof to treat or prevent atm mediated disease, including cancer.

Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein

The present disclosure relates to crystalline form of (s)—n—((s)-1-cyclohexyl-2-{(s)-2-[4-(4-fluoro-benzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide, salts and hydrates thereof. This disclosure also relates to solid oral formulation of (s)—n—((s)-1-cyclohexyl-2-{(s)-2-[4-(4-fluoro-benzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide, pharmaceutically acceptable salts, solvates (including hydrates) thereof, as well as methods of treatment using the same..
Novartis Ag

Antidiabetic tricyclic compounds

Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia..
Merck Sharp & Dohme Corp.

Chemokine cxcr4 receptor modulators and uses related thereto

The disclosure relates to chemokine cxcr4 receptor modulators and uses related thereto. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising compounds disclosed herein or pharmaceutically acceptable salts or prodrugs thereof.
Emory University

Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors

Provided herein are pharmaceutically acceptable salts of 3,5-diaminopyrazoles, for example, pharmaceutically acceptable salts of compounds of formula ia, that are useful for modulating regulated-in-copd kinase activity, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a rc kinase-mediated disorder, disease, or condition..
Axikin Pharmaceuticals, Inc.

Composition for reducing new-onset diabetes

A medical composition for reducing the rate of new-onset diabetes caused by administration of a statin or for inhibiting an increase in blood glucose level by administration of a statin, the composition containing at least one ingredient selected from the group consisting of icosapentaenoic acid and pharmaceutically acceptable salts or esters thereof as an inactive ingredient.. .
Mochida Pharmaceutical Co., Ltd.



Pharmaceutically Acceptable Salts topics:
  • Pharmaceutically Acceptable Salt
  • Pharmaceutically Acceptable Salts
  • Dimethyl Fumarate
  • Amelioration
  • Antivirals
  • Prophylaxis
  • Antiviral Agent
  • Antiviral Agents
  • Hepatitis C
  • Benzimidazole
  • Hepatitis C Virus
  • Neurodegenerative Disease
  • Neurodegenerative Diseases
  • Multiple Sclerosis
  • Degenerative Disease


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Pharmaceutically Acceptable Salts for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Pharmaceutically Acceptable Salts with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.3218

    file did exist - 3585

    1 - 1 - 52